Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset

R. Sharma; A. Dunn; D. Aschman; D. Cheng; A. Wheeler; A. Soni; C. McGuinn; C. Knoll; D. T. Stein; G. Young; J. French; J. Sanders; J. A. Davis; M. Tarantino; M. Lim; R. Gruppo; R. Sidonio; S. Ahuja; S. Carpenter; S. Pipe; A. Shapiro

doi:10.1111/hae.13273

Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset

R. Sharma, A. Dunn, D. Aschman, D. Cheng, A. Wheeler, A. Soni, C. McGuinn, C. Knoll, D. T. Stein, G. Young, J. French, J. Sanders, J. A. Davis, M. Tarantino, M. Lim, R. Gruppo, R. Sidonio, S. Ahuja, S. Carpenter, S. PipeA. Shapiro

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	e385-e388
Journal	Haemophilia
Volume	23
Issue number	4
DOIs	https://doi.org/10.1111/hae.13273
State	Published - Jul 2017
Externally published	Yes

ASJC Scopus subject areas

Hematology
Genetics(clinical)

Access to Document

10.1111/hae.13273

Cite this

Sharma, R., Dunn, A., Aschman, D., Cheng, D., Wheeler, A., Soni, A., McGuinn, C., Knoll, C., Stein, D. T., Young, G., French, J., Sanders, J., Davis, J. A., Tarantino, M., Lim, M., Gruppo, R., Sidonio, R., Ahuja, S., Carpenter, S., ... Shapiro, A. (2017). Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset. Haemophilia, 23(4), e385-e388. https://doi.org/10.1111/hae.13273

Sharma, R, Dunn, A, Aschman, D, Cheng, D, Wheeler, A, Soni, A, McGuinn, C, Knoll, C, Stein, DT, Young, G, French, J, Sanders, J, Davis, JA, Tarantino, M, Lim, M, Gruppo, R, Sidonio, R, Ahuja, S, Carpenter, S, Pipe, S & Shapiro, A 2017, 'Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset', Haemophilia, vol. 23, no. 4, pp. e385-e388. https://doi.org/10.1111/hae.13273

@article{443f99f36e93448b91521cb96f840237,

title = "Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset",

author = "R. Sharma and A. Dunn and D. Aschman and D. Cheng and A. Wheeler and A. Soni and C. McGuinn and C. Knoll and Stein, {D. T.} and G. Young and J. French and J. Sanders and Davis, {J. A.} and M. Tarantino and M. Lim and R. Gruppo and R. Sidonio and S. Ahuja and S. Carpenter and S. Pipe and A. Shapiro",

note = "Funding Information: The ATHNdataset, a HIPAA compliant limited data set under the stewardship of the ATHN, was developed through collaboration with over 135 ATHN-affiliated Haemophilia Treatment Centers across the US. Funding Information: RS, DS, DC, CK, GY, ML, AS, RG, SA and AS have no competing interests to declare. AD has acted as a consultant to Bayer, Baxalta/ Shire, CSL Behring and Medscape and has received research support from Bayer, Baxalta/Shire, CSL Behring, Octapharma, Kedrion and Pfizer. APW has acted as paid consultant for NovoNordisk, Shire and Bayer. CEM has acted as a paid consultant to Baxalta/ Shore and receives research funding as an investigator for Baxalta/ Shire, Biogen and Roche/Genentech. JD serves as a member of the medical advisory board for Novo Nordisc, Bayer Pharmaceuticals, CSL Behring, Baxalta/Shire, Biogen Idec, Grifols and is paid a fee for speaking for Excel CME. MT is a consultant on the advisory board for NovoNordisk, Baxalta, Grifols, Pfizer and Biogen. He is on speaker bureau for Grifols and Biogen and is grant reviewer for Pfizer. He has received research grant from Grifols, he has an investigator initiated study with NovoNordisk and is principal investigator for programme grant for HRSA and CDC. RS has acted as a paid consultant to Biogen, Pfizer, Octapharma, LFB, Hema Biologics, Shire and Emergent Solutions. SC has been a consultant for NovoNordisk, Hema Biologics and has received grant funding from Pfizer. SP serves on the board of directors for ATHN.",

year = "2017",

month = jul,

doi = "10.1111/hae.13273",

language = "English (US)",

volume = "23",

pages = "e385--e388",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders

T2 - A review of impact of national guidance on frequency of RS using the ATHNdataset

AU - Sharma, R.

AU - Dunn, A.

AU - Aschman, D.

AU - Cheng, D.

AU - Wheeler, A.

AU - Soni, A.

AU - McGuinn, C.

AU - Knoll, C.

AU - Stein, D. T.

AU - Young, G.

AU - French, J.

AU - Sanders, J.

AU - Davis, J. A.

AU - Tarantino, M.

AU - Lim, M.

AU - Gruppo, R.

AU - Sidonio, R.

AU - Ahuja, S.

AU - Carpenter, S.

AU - Pipe, S.

AU - Shapiro, A.

N1 - Funding Information: The ATHNdataset, a HIPAA compliant limited data set under the stewardship of the ATHN, was developed through collaboration with over 135 ATHN-affiliated Haemophilia Treatment Centers across the US. Funding Information: RS, DS, DC, CK, GY, ML, AS, RG, SA and AS have no competing interests to declare. AD has acted as a consultant to Bayer, Baxalta/ Shire, CSL Behring and Medscape and has received research support from Bayer, Baxalta/Shire, CSL Behring, Octapharma, Kedrion and Pfizer. APW has acted as paid consultant for NovoNordisk, Shire and Bayer. CEM has acted as a paid consultant to Baxalta/ Shore and receives research funding as an investigator for Baxalta/ Shire, Biogen and Roche/Genentech. JD serves as a member of the medical advisory board for Novo Nordisc, Bayer Pharmaceuticals, CSL Behring, Baxalta/Shire, Biogen Idec, Grifols and is paid a fee for speaking for Excel CME. MT is a consultant on the advisory board for NovoNordisk, Baxalta, Grifols, Pfizer and Biogen. He is on speaker bureau for Grifols and Biogen and is grant reviewer for Pfizer. He has received research grant from Grifols, he has an investigator initiated study with NovoNordisk and is principal investigator for programme grant for HRSA and CDC. RS has acted as a paid consultant to Biogen, Pfizer, Octapharma, LFB, Hema Biologics, Shire and Emergent Solutions. SC has been a consultant for NovoNordisk, Hema Biologics and has received grant funding from Pfizer. SP serves on the board of directors for ATHN.

PY - 2017/7

Y1 - 2017/7

UR - http://www.scopus.com/inward/record.url?scp=85019716793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019716793&partnerID=8YFLogxK

U2 - 10.1111/hae.13273

DO - 10.1111/hae.13273

M3 - Letter

C2 - 28544271

AN - SCOPUS:85019716793

SN - 1351-8216

VL - 23

SP - e385-e388

JO - Haemophilia

JF - Haemophilia

IS - 4

ER -

Radionuclide synovectomy/synoviorthesis (RS) in persons with bleeding disorders: A review of impact of national guidance on frequency of RS using the ATHNdataset

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this